Charmacy Pharmaceutical Co., Ltd. (HKG:2289)
Hong Kong · Delayed Price · Currency is HKD 5.80
-0.08 (-1.36%)
Jan 30, 2026, 3:55 PM HKT
Charmacy Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,188 | 4,385 | 4,348 | 4,141 | 3,763 | 3,962 |
Other Revenue | 54.92 | 50.34 | 56.11 | 34.61 | 30.55 | 29.5 |
| 4,243 | 4,435 | 4,404 | 4,175 | 3,794 | 3,992 | |
Revenue Growth (YoY) | -5.32% | 0.72% | 5.47% | 10.06% | -4.96% | 14.29% |
Cost of Revenue | 3,931 | 4,115 | 4,115 | 3,907 | 3,560 | 3,754 |
Gross Profit | 312.58 | 320.88 | 288.38 | 268.61 | 234.12 | 237.4 |
Selling, General & Admin | 171.97 | 175.27 | 170 | 162.57 | 151.85 | 131.67 |
Other Operating Expenses | 10.06 | 10.33 | 9.3 | 10.07 | 8.13 | 6.28 |
Operating Expenses | 181.54 | 185.67 | 180.11 | 175.12 | 159.69 | 149.33 |
Operating Income | 131.05 | 135.21 | 108.28 | 93.49 | 74.42 | 88.08 |
Interest Expense | -60.42 | -62.46 | -41.93 | -35.07 | -41.52 | -31.74 |
Interest & Investment Income | 2.25 | 3.98 | 4.3 | 4.6 | 3.8 | 4.02 |
Currency Exchange Gain (Loss) | -0.27 | -0.26 | -0.36 | -0.75 | 0.14 | 0.02 |
Other Non Operating Income (Expenses) | -5.14 | -3.6 | -4.11 | -6.99 | -4.01 | -5.67 |
EBT Excluding Unusual Items | 67.46 | 72.87 | 66.17 | 55.28 | 32.83 | 54.71 |
Impairment of Goodwill | -0.03 | -0.03 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | -0.1 | - | - | - |
Gain (Loss) on Sale of Assets | -0.08 | 0.31 | 0.05 | 65.84 | 0.15 | 0.02 |
Asset Writedown | -0.17 | -0.33 | -0.01 | - | -0.01 | - |
Other Unusual Items | -2.29 | -1.62 | 1.32 | 0.94 | 0.01 | 0.02 |
Pretax Income | 64.89 | 71.19 | 67.42 | 122.05 | 32.98 | 54.74 |
Income Tax Expense | 16.62 | 17.91 | 16.07 | 31.58 | 9.83 | 14.19 |
Earnings From Continuing Operations | 48.28 | 53.28 | 51.34 | 90.47 | 23.15 | 40.56 |
Net Income | 48.28 | 53.28 | 51.34 | 90.47 | 23.15 | 40.56 |
Net Income to Common | 48.28 | 53.28 | 51.34 | 90.47 | 23.15 | 40.56 |
Net Income Growth | -6.69% | 3.78% | -43.25% | 290.76% | -42.91% | 1.00% |
Shares Outstanding (Basic) | 108 | 108 | 108 | 108 | 108 | 108 |
Shares Outstanding (Diluted) | 108 | 108 | 108 | 108 | 108 | 108 |
Shares Change (YoY) | 0.01% | -0.01% | 0.00% | 0.01% | -0.01% | 0.01% |
EPS (Basic) | 0.45 | 0.49 | 0.48 | 0.84 | 0.21 | 0.38 |
EPS (Diluted) | 0.45 | 0.49 | 0.48 | 0.84 | 0.21 | 0.38 |
EPS Growth | -6.70% | 3.79% | -43.25% | 290.72% | -42.90% | 1.00% |
Free Cash Flow | 246.78 | 90.31 | -137.39 | 35.46 | -44.58 | 79.1 |
Free Cash Flow Per Share | 2.29 | 0.84 | -1.27 | 0.33 | -0.41 | 0.73 |
Dividend Per Share | 0.450 | 0.450 | 0.300 | 0.450 | - | 0.200 |
Dividend Growth | 50.00% | 50.00% | -33.33% | - | - | - |
Gross Margin | 7.37% | 7.23% | 6.55% | 6.43% | 6.17% | 5.95% |
Operating Margin | 3.09% | 3.05% | 2.46% | 2.24% | 1.96% | 2.21% |
Profit Margin | 1.14% | 1.20% | 1.17% | 2.17% | 0.61% | 1.02% |
Free Cash Flow Margin | 5.82% | 2.04% | -3.12% | 0.85% | -1.18% | 1.98% |
EBITDA | 150.32 | 155.71 | 129.95 | 121.03 | 103.52 | 109.87 |
EBITDA Margin | 3.54% | 3.51% | 2.95% | 2.90% | 2.73% | 2.75% |
D&A For EBITDA | 19.27 | 20.5 | 21.68 | 27.54 | 29.09 | 21.79 |
EBIT | 131.05 | 135.21 | 108.28 | 93.49 | 74.42 | 88.08 |
EBIT Margin | 3.09% | 3.05% | 2.46% | 2.24% | 1.96% | 2.21% |
Effective Tax Rate | 25.61% | 25.16% | 23.84% | 25.87% | 29.80% | 25.91% |
Revenue as Reported | 4,243 | 4,435 | 4,404 | 4,175 | 3,794 | 3,992 |
Advertising Expenses | - | 6.08 | 11.52 | 8.89 | 9.22 | 3.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.